Xydalba Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

xydalba

abbvie deutschland gmbh & co. kg - dalbavancin hydrochloride - soft tissue infections; skin diseases, bacterial - antibakterijski lijekovi za sistemsku primjenu, - liječenje akutnih bakterijskih infekcija kože i strukture kože (absssi) u odraslih osoba.

Savene Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

savene

clinigen healthcare b.v. - dexrazoxane hydrochloride - ekstravaziranje dijagnostičkih i terapeutskih materijala - svi ostali terapeutski proizvodi - savene je indiciran za liječenje antraciklin ekstravazacija.

Segluromet Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

segluromet

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - dijabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Scandonest 30 mg/ml otopina za injekciju Κροατία - Κροατικά - HALMED (Agencija za lijekove i medicinske proizvode)

scandonest 30 mg/ml otopina za injekciju

apolonia d.o.o., dubrova 308, labin - mepivacaini hydrochloridum - otopina za injekciju - 30 mg/ml - urbroj: 1 ml otopine za injekciju sadrži 30 mg mepivakainklorida

Zolsketil pegylated liposomal Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

zolsketil pegylated liposomal

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Quviviq Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

quviviq

idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - poremećaji uvođenja i održavanja spavanja - psycholeptics - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.

NATRII CHLORIDI INFUNDIBILE COMPOSITUM (RINGER RASTVOR) 8.6 g/1000 mL+ 0.33 g/1000 mL+ 0.3 g/1000 mL rastvor za infuziju Βοσνία - Ερζεγοβίνη - Κροατικά - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

natrii chloridi infundibile compositum (ringer rastvor) 8.6 g/1000 ml+ 0.33 g/1000 ml+ 0.3 g/1000 ml rastvor za infuziju

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - kalcijumhlorid, kalijumhlorid, natrijumhlorid - rastvor za infuziju - 8.6 g/1000 ml+ 0.33 g/1000 ml+ 0.3 g/1000 ml - 1000 ml rastvora za infuziju sadrži: 8,60 g natrijumhlorida, 0,33 g kalcijumhlorida i 0,30 g kalijumhlorida